Current Gastroenterology Reports

, Volume 6, Issue 1, pp 37–43 | Cite as

Hepatocellular carcinoma: Updates in primary prevention

  • Will J. FechtJr
  • Alex S. Befeler
Article

Abstract

Hepatocellular carcinoma is a significant cause of mortality worldwide and a growing problem in the United States. Treatment options are often limited, and median survival is less than 1 year. Thus, prevention may provide the best opportunity to alter the natural history of this disease. Primary prevention is best exemplified by the successes of such public health measures as universal hepatitis B vaccination. Such antiviral therapies as interferon may also have a role. Lessons can be learned from complementary and alternative medicine. Nevertheless, more work is needed in understanding hepatocarcinogenesis and in developing models to assess potential chemopreventive agents.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Befeler AS, Di Bisceglie AM: Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 2002, 122:1609–1619. This article outlines recommendations for diagnosis and treatment of HCC.PubMedCrossRefGoogle Scholar
  2. 2.
    Bosch FX, Ribes J, Borras J: Epidemiology of primary liver cancer. Semin Liver Dis 1999, 19:271–285.PubMedCrossRefGoogle Scholar
  3. 3.
    El-Serag HB, Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999, 340:745–750.PubMedCrossRefGoogle Scholar
  4. 4.
    Jemal A, Murray T, Samuels A, et al.: Cancer statistics 2003. CA Cancer J Clin 2003, 53:5–26.PubMedGoogle Scholar
  5. 5.
    El-Serag HB, Davila J, Petersen N: The incidence of hepatocellular carcinoma in the United States: Is it still rising? Gastroenterology 2003, 124(Suppl 1):A-690.Google Scholar
  6. 6.
    Thorgeirsson SS, Grisham JW: Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002, 31:339–46. A compact up-to-date review of what is known about hepatocarcinogenesis. A better understanding of the mechanisms of HCC development is essential to progress in prevention of HCC.PubMedCrossRefGoogle Scholar
  7. 7.
    Nzeako UC, Goodman ZD, Ishak KG: Hepatocellular carcinoma in cirrhotic and noncirrhotic livers: a clinico-histopathologic study of 804 North American patients. Am J Clin Pathol 1996, 105:65–75.PubMedGoogle Scholar
  8. 8.
    El-Serag HB: Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2001, 5:87–107.PubMedCrossRefGoogle Scholar
  9. 9.
    El-Serag HB, Mason AC, Key C: Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in United States. Hepatology 2001, 33:62–65.PubMedCrossRefGoogle Scholar
  10. 10.
    Blum HE: Molecular targets for prevention of hepatocellular carcinoma. Dig Dis 2002, 20:81–90. This article provides links between our understanding of molecular hepatocarcinogenesis and potential prevention strategies.PubMedCrossRefGoogle Scholar
  11. 11.
    Tamimi RM, Lagiou P, Adami HO et al.: Prospects for chemoprevention of cancer. J Intern Med 2002, 251:286–300.PubMedCrossRefGoogle Scholar
  12. 12.
    Monto A, Wright TL: The epidemiology and prevention of hepatocellular carcinoma. Semin Oncol 2001, 28:441–449.PubMedCrossRefGoogle Scholar
  13. 13.
    Yu MC, Yuan J, Ross RK, et al.: Presence of antibodies to the hepatitis B surface antigen is associated with an excess risk for hepatocellular carcinoma among non-Asians in Los Angeles county, California. Hepatology 1997, 25:226–228.PubMedCrossRefGoogle Scholar
  14. 14.
    Chang H, Chen C, Lai M, et al.: Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 1997, 336:1855–1859.PubMedCrossRefGoogle Scholar
  15. 15.
    Huang K, Lin S: Nationwide vaccination: a success story in Taiwan. Vaccine 2000, 18(Suppl 1):S34-S38.Google Scholar
  16. 16.
    Kao J, Chen D: Recent updates in hepatitis vaccination and the prevention of hepatocellular carcinoma. Int J Cancer 2002, 97:269–271.PubMedCrossRefGoogle Scholar
  17. 17.
    Wild CP, Hall AJ: Primary prevention of hepatocellular carcinoma in developing countries. Mutat Res 2000, 462:381–393.PubMedCrossRefGoogle Scholar
  18. 18.
    Prince A: Prevention of liver cancer and cirrhosis by vaccine. Clin Lab Med 1996, 16:493–505.PubMedGoogle Scholar
  19. 19.
    Kane M, Banatvala J, Da Villa G, et al.: Are booster immunizations needed for lifelong hepatitis B immunity? Lancet 2000, 355:561–565.CrossRefGoogle Scholar
  20. 20.
    Camma C, Giunta M, Andreone P, et al.: Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 2001, 34:593–602.PubMedCrossRefGoogle Scholar
  21. 21.
    Baffis V, Shrier I, Sherker A, et al.: Use of interferon for prevention of hepatocellular carcinoma in cirrhotic patients with hepatitis B or hepatitis C virus infection. Ann Intern Med 1999, 131:696–701.PubMedGoogle Scholar
  22. 22.
    Colombo M: Hepatocellular carcinoma in patients with HCV. Baillieres Best Pract Res Clin Gastroenterol 2000, 14:327–329.PubMedCrossRefGoogle Scholar
  23. 23.
    Centers for Disease Control and Prevention. http://ww.cdc.gov/ncidod/diseases/hepatitis/c/faq.htm#6b Accessed September 30, 2003.Google Scholar
  24. 24.
    Jaeckel E, Cornberg M, Wedemeyer H, et al.: Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001, 345:1452–1457.PubMedCrossRefGoogle Scholar
  25. 25.
    Fried MW, Shiffman ML, Reddy KR, et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975–982.PubMedCrossRefGoogle Scholar
  26. 26.
    Shiratoi Y, Imazeki F, Moriyama M, et al.: Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000, 132:517–524.Google Scholar
  27. 27.
    Di Bisceglie AM, Carithers RL, Gores GJ: Hepatocellular carcinoma. Hepatology 1998, 28:1161–1165.CrossRefGoogle Scholar
  28. 28.
    Donato F, Boffetta P, Puoti M: A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998, 75:347–54.PubMedCrossRefGoogle Scholar
  29. 29.
    Tagger A, Donato F, Ribero ML, et al.: Case-control study on hepatitis C virus (HCV) as a risk factor for hepatocellular carcinoma: the role of HCV genotypes and the synergism with hepatitis B virus and alcohol. Int J Cancer 1999, 81:695–699.PubMedCrossRefGoogle Scholar
  30. 30.
    Mori M, Hara M, Wada I, et al.: Prospective study of hepatitis B and C viral infections, cigarette smoking, alcohol consumption, and other factors associated with hepatocellular carcinoma risk in Japan. Am J Epidemiol 2000, 151:131–139.PubMedGoogle Scholar
  31. 31.
    Riley TR, Smith JP: Preventive care in chronic liver disease. J Gen Intern Med 1999, 14:699–704.PubMedCrossRefGoogle Scholar
  32. 32.
    Yu S: Primary prevention of hepatocellular carcinoma. J Gastroenterol Hepatol 1995, 10:674–682.PubMedGoogle Scholar
  33. 33.
    Ross RK, Yuan JM, Yu MC, et al.: Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet 1992, 339:943–946.PubMedCrossRefGoogle Scholar
  34. 34.
    Wang J, Shen X, He X, et al.: Protective alterations in phase 1 and 2 metabolism of aflatoxin b1 by oltipraz in resident of Qidong, People’s Republic of China. J Natl Cancer Inst 1999, 91:347–354.PubMedCrossRefGoogle Scholar
  35. 35.
    Bacon BR, Di Bisceglie AM: Hereditary hemochromatosis. In Liver Disease: Diagnosis and Management. Edited by Bacon BR.New York: Churchill Livingstone; 2000:140–149.Google Scholar
  36. 36.
    Plesch FN, Kubicka S, Manns MP: Prevention of hepatocellular carcinoma in chronic liver disease: molecular markers and clinical implications. Dig Dis 2001, 19:338–344.PubMedCrossRefGoogle Scholar
  37. 37.
    Niederau C, Fischer R, Purschel A, et al.: Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996, 110:1107–1119.PubMedCrossRefGoogle Scholar
  38. 38.
    Niederau C, Fischer R, Sonnenberg A, et al.: Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med 1985, 313:1256–1262.PubMedCrossRefGoogle Scholar
  39. 39.
    Fargion S, Mandelli C, Piperno A, et al.: Survival and prognostic factors in 212 Italian patients with genetic hemochromatosis. Hepatology 1992, 15:655–659.PubMedCrossRefGoogle Scholar
  40. 40.
    Muto Y, Moriwaki H, Ninomiya M, et al.: Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma: Hepatoma Prevention Study Group. N Engl J Med 1996, 334:1561–1567.PubMedCrossRefGoogle Scholar
  41. 41.
    Kumada H: Long-term treatment of chronic hepatitis C with glycyrrhizin Stronger Neo-Minophagen C (SNMC) for preventing liver cirrhosis and hepatocellular carcinoma. Oncology 2002, 62(Suppl 1):94–100.PubMedCrossRefGoogle Scholar
  42. 42.
    Arase Y, Ikeda K, Murashima N, et al.: The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 1997, 79:1494–1500.PubMedCrossRefGoogle Scholar
  43. 43.
    Okita K, Sakaida I, Hino K: Current strategies for chemoprevention of hepatocellular carcinoma. Oncology 2002, 62(Suppl 1):24–28.PubMedCrossRefGoogle Scholar
  44. 44.
    Oka H, Yamamoto S, Kuroki T, et al.: Prospective study of chemoprevention of hepatocellular carcinoma with shosaiko- to (TJ-9). Cancer 1995, 76:743–749.PubMedCrossRefGoogle Scholar
  45. 45.
    Horn W: General pharmacology, toxicology and future clinical development of HOE 077. J Hepatol 1991, 13(Suppl 3):S63-S65.PubMedCrossRefGoogle Scholar
  46. 46.
    Steinbach G, Lynch PM, Phillips RK, et al.: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000, 342:1946–1952.PubMedCrossRefGoogle Scholar
  47. 47.
    Hu K: Rationale and feasibility of chemoprevention of hepatocellular carcinoma by cyclooxygenase-2 inhibitors. J Lab Clin Med 2002, 139:234–243.PubMedCrossRefGoogle Scholar
  48. 48.
    Chuang SE, Kuo ML, Hsu CH, et al.: Curcumin-containing diet inhibits diethynitrosamine-induced murices hepatocarcinogenesis. Carcinogenesis 2000, 21:331–335.PubMedCrossRefGoogle Scholar
  49. 49.
    Cheng AL, Hsu CH, Lin JK, et al.: Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001, 21:2895–2900.PubMedGoogle Scholar

Copyright information

© Current Science Inc 2004

Authors and Affiliations

  • Will J. FechtJr
    • 1
  • Alex S. Befeler
    • 1
  1. 1.Division of Gastroenterology and HepatologySaint Louis University School of MedicineSt. LouisUSA

Personalised recommendations